JFJennifer Franke

Jennifer Franke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jennifer Franke has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Roles for cardiologists in government, research councils and regulatory sectors

    by Liesl Zühlke, Jennifer Franke, Martin R Cowie

    Participating in a national council, such as the German Interoperability Council for Digital Medicine, allows healthcare professionals to contribute to national efforts in developing interoperability specifications for digitalised healthcare. General requirements include proven specialist knowledge with at least 5 years of professional experience in healthcare, information technology (IT) and standardisation in the healthcare sector. Applicants must also belong to a legal entity listed in the Health IT Interoperability Governance Regulation. …


  • Open Access

    Challenges and Burdens in the Coronary Artery Disease Care Pathway for Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Narrative Review

    by Monika Kodeboina, Kerstin Piayda, Inge Jenniskens, Pearl Vyas, Sara Chen, Ramon Julian Pesigan, Nicole Ferko, Barkha P. Patel, Annamaria Dobrin, Jayson Habib, et al.

    Clinical and economic burdens exist within the coronary artery disease (CAD) care pathway despite advances in diagnosis and treatment and the increasing utilization of percutaneous coronary intervention (PCI). However, research presenting a comprehensive assessment of the challenges across this pathway is scarce. This contemporary review identifies relevant studies related to inefficiencies in the diagnosis, treatment, and management of CAD, including clinician, patient, and economic burdens. Studies demonstrating the benefits of integration and automation within the catheterization laboratory and across the CAD care pathway were also included. Most studies were published in the last 5–10 years and focused on North America and Europe. The review demonstrated multiple potentially avoidable inefficiencies, with a focus on access, appropriate use, conduct, and follow-up related to PCI. Inefficiencies included misdiagnosis, delays in emergency care, suboptimal testing, longer procedure times, risk of recurrent cardiac events, incomplete treatment, and challenges accessing and adhering to post-acute care. Across the CAD pathway, this review revealed that high clinician burnout, complex technologies, radiation, and contrast media exposure, amongst others, negatively impact workflow and patient care. Potential solutions include greater integration and interoperability between technologies and systems, improved standardization, and increased automation to reduce burdens in CAD and improve patient outcomes.


  • Career paths for cardiologists in industry: exploring opportunities in hospital management, medical device industry and biotech

    by Matthew J Daniels, Sara Sheikhzadeh, Jennifer Franke

    Global economic challenges and heathcare policy changes call for a strong interaction between healthcare managers and clinicians. In-depth knowledge of the healthcare system and clinical processes is crucial for improving medical care and hospital performance. Studies indicate that improving hospital leadership, particularly in cultural competency, positively affects the overall hospital performance.1 2 Tasi et al showed that physician leadership was independently associated with higher average quality ratings, suggesting that physician leaders may possess skills or management approaches that positively affect hospital quality and care value. Although physician leadership was associated with more inpatient days in hospital, total revenue and profit margin were not impacted compared with non-physician-led hospitals.3


  • Career paths for cardiologists in industry: pharmaceutical, medical insurance, health technology and management consulting

    by Sanjay Gandhi, Jennifer Franke, Rujuta Shrotriya

    The pharmaceutical industry presents several opportunities for cardiologists. Those with significant basic research background are well positioned in roles related to drug development and discovery. These roles range from molecule and target identification in preclinical research to later-stage clinical development and operations. Engagement with academia to provide a pipeline of newer drugs and discoveries in the field of cardiovascular and cardiorenal–metabolic disorders is also within the purview of research and development. On the other hand, cardiologists with hands-on clinical expertise and clinical study experience are better suited as therapeutic area leaders and medical affairs professionals and may be engaged with brand teams in product launch, market access and reimbursement, marketing communications and postmarket surveillance activities.1 This could involve a wide spectrum of responsibilities from clinical evidence generation including clinical studies, drug safety, implementation research, and interactions with regulatory bodies and medical communities at large.


  • Transitioning from clinical cardiology to industry: general considerations

    by Matthew J Daniels, George Harston, Jennifer Franke

    The earlier you transition, the less differentiated you are from peers or even non-clinically trained colleagues, and your healthcare knowledge will be more theoretical. You will have a wider range of potential employers within which to grow, but entry will be lower on the career ladder, and the value you bring as an individual will be less specific. While academic and clinical super-specialisation are not necessarily attributes an industry employer seeks, the experience and skills that doctors in more senior positions have acquired relating to management, patient pathways and strategic decision-making can make senior physicians attractive to recruit. Entry points are manifold: companies recruit clinicians via internal/external talent acquisition and provide their employees with incentives to recommend talents from personal networks. Platforms such as …

  • Coexistence and outcome of coronary artery disease in Takotsubo syndrome

    by L Christian Napp, Victoria L Cammann, Milosz Jaguszewski, Konrad A Szawan, Manfred Wischnewsky, Sebastiano Gili, Maike Knorr, Susanne Heiner, Rodolfo Citro, Eduardo Bossone, et al.

    Aims: Takotsubo syndrome (TTS) is an acute heart failure syndrome, which shares many features with acute coronary syndrome (ACS). Although TTS was initially described with angiographically normal coronary arteries, smaller studies recently indicated a potential coexistence of coronary artery disease (CAD) in TTS patients. This study aimed to determine the coexistence, features, and prognostic role of CAD in a large cohort of patients with TTS. Methods and results: Coronary anatomy and CAD were studied in patients diagnosed with TTS. Inclusion criteria were compliance with the International Takotsubo Diagnostic Criteria for TTS, and availability of original coronary angiographies with ventriculography performed during the acute phase. Exclusion criteria were missing views, poor quality of angiography loops, and angiography without ventriculography. A total of 1016 TTS patients were studied. Of those, 23.0% had obstructive CAD, 41.2% had non-obstructive CAD, and 35.7% had angiographically normal coronary arteries. A total of 47 patients (4.6%) underwent percutaneous coronary intervention, and 3 patients had acute and 8 had chronic coronary artery occlusion concomitant with TTS, respectively. The presence of CAD was associated with increased incidence of shock, ventilation, and death from any cause. After adjusting for confounders, the presence of obstructive CAD was associated with mortality at 30 days. Takotsubo syndrome patients with obstructive CAD were at comparable risk for shock and death and nearly at twice the risk for ventilation compared to an age- and sex-matched ACS cohort. Conclusions: Coronary artery disease frequently coexists in TTS patients, presents with the whole spectrum of coronary pathology including acute coronary occlusion, and is associated with adverse outcome. Trial registration: ClinicalTrials.gov number: NCT01947621.


  • PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM

    by O. Reifsnider, A. Kansal, J. Franke, J. Lee, J.T. George, M. Brueckmann, S. Kaspers, S. Brand, A. Ustyugova, S. Linden, et al.


  • Prognostic value of preprocedural 6-min walk test in patients undergoing transcatheter mitral valve repair—insights from the German transcatheter mitral valve interventions registry

    by Jakob Ledwoch, Jennifer Franke, Edith Lubos, Peter Boekstegers, Miriam Puls, Taoufik Ouarrak, Stephan von Bardeleben, Christian Butter, Joachim Schofer, Ralf Zahn, et al.

    The 6-min walk test (6 MWT) has been established as an important tool for functional assessment in heart failure patients. However, its prognostic impact on the outcome in subjects with mitral regurgitation undergoing transcatheter mitral valve repair is unknown.


  • Acute Stroke Intervention

    by Stefan C. Bertog, Iris Q. Grunwald, Anna Luisa Kühn, Jennifer Franke, Ilona Hofmann, Horst Sievert

  • Safety of percutaneous left atrial appendage closure with the amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation

    by Jens Wiebe, Stefan Bertog, Jennifer Franke, Olga Wettstein, Katharina Lehn, Ilona Hofmann, Laura Vaskelyte, Horst Sievert

    Objective: To evaluate the safety of percutaneous left atrial appendage (LAA) closure with the Amplatzer Cardiac Plug (ACP) in patients with nonvalvular atrial fibrillation (AF) who are not eligible for oral anticoagulation with warfarin.Background: Anticoagulation is the treatment of choice for prevention of strokes in patients with AF, but some patients have contraindications to anticoagulation.Methods: A total of 60 patients with a CHA2DS2‐VASc score of at least 1 and contraindications to warfarin who underwent percutaneous LAA closure with the ACP were included. Stroke risk assessment was performed with the CHADS2 and CHA2DS2‐VASc score and the bleeding risk was calculated with the HAS‐BLED‐score. Follow‐up included office visits, telephone inquiries, and mail contact.Results: Mean CHADS2‐, CHA2DS2‐VASc‐, and HAS‐BLED scores were 2.6 (± 1.4), 4.3 (± 1.7), and 3.3 (± 1.0), respectively. Twenty‐five percent had a history of previous bleeding without oral anticoagulation and 63.3% while receiving oral anticoagulation. In 36.7% other contraindications to warfarin were present. Procedural success was achieved in 95%. Mean follow‐up time was 1.8 (1.0–2.8) years. The estimated annual stroke risk based on the CHADS2‐score was 5.8%. The estimated annual bleeding risk on warfarin based on the HAS‐BLED score was 3.7%. During follow‐up, the annual incidence of stroke was 0%. Major bleeding complications occurred in 1.9% annually.Conclusions: Percutaneous LAA closure with the ACP in patients with contraindications to oral anticoagulation is safe. The stroke and bleeding risk after percutaneous LAA closure is lower than predicted by conventional risk scores.